We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
51
uniQure
QURE
$3.2B
$1.52M 0.35%
+292,850
New +$1.68M
APLS
52
DELISTED
Apellis Pharmaceuticals
APLS
$1.51M 0.34%
+25,700
New +$1.64M
LLY icon
53
Eli Lilly
LLY
$1.06T
$1.45M 0.33%
+1,865
New +$1.33M
TEVA icon
54
Teva Pharmaceuticals
TEVA
$41.4B
$1.43M 0.33%
101,626
-9,700
-9% -$122K
NGM
55
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.3M 0.29%
+816,581
New +$1.21M
VKTX icon
56
Viking Therapeutics
VKTX
$3.9B
$1.18M 0.27%
14,401
-239,750
-94% -$10.7M
KNSA icon
57
Kiniksa Pharmaceuticals
KNSA
$5.93B
$1.18M 0.27%
59,700
-45,300
-43% -$885K
NVNO
58
enVVeno Medical
NVNO
$6.78M
$1.1M 0.25%
+5,764
New +$1.03M
ARVN icon
59
Arvinas
ARVN
$579M
$1.08M 0.25%
+26,200
New +$1.14M
DCTH icon
60
Delcath Systems
DCTH
$540M
$1.04M 0.24%
218,973
-12,329
-5% -$53.2K
CERE
61
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$1.03M 0.23%
24,259
-86,441
-78% -$3.63M
ANGO icon
62
AngioDynamics
ANGO
$636M
$900K 0.2%
153,362
+20,400
+15% +$121K
SLN
63
Silence Therapeutics
SLN
$574M
$866K 0.2%
40,090
+39,900
+21,000% +$867K
GOSS icon
64
Gossamer Bio
GOSS
$87M
$865K 0.2%
732,628
+19,600
+3% +$21.6K
GLST
65
DELISTED
Global Star Acquisition, Inc. Class A Common Stock
GLST
$857K 0.19%
80,000
– –
VYGR icon
66
Voyager Therapeutics
VYGR
$195M
$852K 0.19%
91,534
-94,360
-51% -$797K
CATX icon
67
Perspective Therapeutics
CATX
$342M
$805K 0.18%
67,673
+63,453
+1,504% +$541K
KVACU
68
DELISTED
Keen Vision Acquisition Corp Units
KVACU
$788K 0.18%
75,000
– –
ATNM icon
69
Actinium Pharmaceuticals
ATNM
$25.1M
$783K 0.18%
+100,000
New +$643K
KPRX icon
70
Kiora Pharmaceuticals
KPRX
$11.5M
$777K 0.18%
+122,222
New +$683K
GRCE
71
Grace Therapeutics
GRCE
$34.7M
$745K 0.17%
217,381
+182,849
+530% +$539K
MORF
72
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$693K 0.16%
+19,701
New +$660K
KYMR icon
73
Kymera Therapeutics
KYMR
$8.76B
$643K 0.15%
+16,000
New +$572K
CRBP icon
74
Corbus Pharmaceuticals
CRBP
$187M
$628K 0.14%
+16,000
New +$395K
TXMD icon
75
TherapeuticsMD
TXMD
$24.3M
$623K 0.14%
272,160
– –
1 2
3
4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.